ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Assessment Questionnaire (HAQ)"

  • Abstract Number: 2453 • ACR Convergence 2024

    Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study

    Elvira Lesmana1, Ashley Keehn2, Anukul Karn3, Andrea Pauly4, Margaret Breen-Lyles2, Adam L Edwinson2, Madhusudan Grover5 and Ashima Makol5, 1Mayo Clinic, Rochester, MN, New York, NY, 2Mayo Clinic, Rochester, MN, Rochester, 3Mayo Clinic, Rochester, MN, Farmington Hills, MI, 4Mayo Clinic Rochester, Rochester, MN, 5Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
  • Abstract Number: 0122 • ACR Convergence 2024

    Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome

    Evelyn Aranda Cano1, Jessica Roldan Ortega2, Yaneli Juárez-Vicuña3, Fausto Sánchez Muñoz4, Itzel Palafox Sosa5, Luz Angelica Viruel-Mejia6, David Vera Bustamante7, Luis H. Silveira Torre8, Angélica Vargas Guerrero9, Mayra Nadia Quintanar-Cuevas10, Erick Giovanny Bautista Jímenez11 and Laura Aline Martinez-Martinez12, 1Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, 2Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 3Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, 4Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 5Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, 6Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, 7Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, 8Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 9Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 10Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, 11Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, 12Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
  • Abstract Number: 0355 • ACR Convergence 2024

    Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials

    Vibeke Strand1, Puja Khanna2, Alan Kivitz3, Nana Kragh4, Aletta Falk5, Rehan Azeem6, Hugues Santin-Janin7 and Herbert Baraf8, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2University of Michigan, Ann Arbor, MI, 3Altoona Center for Clinical Research, Duncansville, PA, 4Sobi, Kongens Lyngby, Denmark, 5Sobi, Stockholm, Sweden, 6Sobi Inc., Waltham, MA, 7Sobi, BETTENDORF (68560), France, 8Center for Rheumatology and Bone Research, Wheaton, MD

    Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
  • Abstract Number: 0229 • ACR Convergence 2023

    Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout

    HYUNSUE DO and Kiwon Moon, Kangwon National University Hospital, Seoul, South Korea

    Background/Purpose: Gout, which is a prevalent form of inflammatory arthritis, is generally considered to be more effectively managed through medication. Besides of maintaining medication, they…
  • Abstract Number: 0386 • ACR Convergence 2023

    Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis

    Mohammad Movahedi1, Kangping Cui2, George Tomilnson3, Angela Cesta3, xiuying Li3 and Claire Bombardier4, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Sunnybrook Hospital, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: The relationship between social determinants of health (SDH) (e.g. income, education, and employment status) and disease outcomes in the RA population is not well…
  • Abstract Number: 0839 • ACR Convergence 2023

    Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study

    Peter C. Taylor1, Georg Schett2, Fowzia Ibrahim3, Bei Zhou4, Jocelyn H. Leu5, Sophia G. Liva5, Qingmin Wang5, Ricardo Rojo Cella5, Chetan S. Karyekar5 and Kaiyin Fei5, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 3Janssen Research & Development, LLC, High Wycombe, United Kingdom, 4Janssen Research & Development, LLC, Chesterbrook, PA, 5Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: RA is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission…
  • Abstract Number: 1108 • ACR Convergence 2023

    Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

    Brian LaMoreaux1, Chelsea McKibbon2, Katie Obermeyer1, Lissa Padnick-Silver1, Gerald Smith2, Jiaxuan Wang2 and Haridarshan Patel1, 1Horizon Therapeutics, Deerfield, IL, 2Cytel Inc., Vancouver, BC, Canada

    Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
  • Abstract Number: 1278 • ACR Convergence 2023

    Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability

    Manja van Wissen1, Maaike gademan1, Cornelia van den Ende2, Max Teuwen1, Wilfred Peter1, Dirkjan van Schaardenburg3, Alfons den Broeder2, Thea Vliet Vlieland4 and Salima van Weely1, 1Leiden University Medical Center, Leiden, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Reade, Amsterdam, Netherlands, 4Leids University Medical Center, Leiden, Netherlands

    Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
  • Abstract Number: 1304 • ACR Convergence 2023

    Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy

    Vivian Bykerk1, Isabel Castrejon2, Vibeke Strand3, Stephanie Dahan4, Raul Castellanos-Moreira5, Leo Chen6 and Wayne Little4, 1Department of Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3Stanford University, Palo Alto, CA, 4Bristol Myers Squibb, Princeton, NJ, 5Bristol Myers Squibb, Madrid, Spain, 6Syneos Health, Vancouver, BC, Canada

    Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
  • Abstract Number: 1421 • ACR Convergence 2023

    Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)

    Laura Coates1, Carlo Selmi2, Georg Schett3, Pascal Richette4, Felipe Julio Ramirez Garcia5, Wim Noël6, Emmanouil Rampakakis7, Miriam Zimmermann8, Mohamed Sharaf9 and Dennis McGonagle10, 1University of Oxford, Oxford, United Kingdom, 2Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 4Lariboisière Hospital, Paris, France, 5Hospital Clínic, Barcelona, Spain, 6Janssen, Zemst, Belgium, 7JSS Medical Research, Saint-Laurent, QC, Canada, 8Janssen Pharmaceuticals, Zug, Switzerland, 9Immunology, Janssen MEA, Dubai, United Arab Emirates, 10Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom

    Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…
  • Abstract Number: 1981 • ACR Convergence 2023

    The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up

    Olga Sleglova1, Jiri Baloun2, Jindriska Gatterova1, Xiao Svec1, Olga Ruzickova1, Karel Pavelka3 and Ladislav Senolt4, 1Rheumatology Institute, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Hand osteoarthritis (HOA) is a heterogeneous disorder with two main subtypes, non-erosive and erosive. The progression of HOA is assessed by various radiographic scoring…
  • Abstract Number: 2229 • ACR Convergence 2023

    Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies

    Laura Coates1, Iain McInnes2, Sibel Aydin3, Mitsumasa Kishimoto4, Philip J. Mease5, May Shawi6, Miriam Zimmermann7, Emmanouil Rampakakis8, Frederic Lavie9 and Dennis McGonagle10, 1University of Oxford, Oxford, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, 4Kyorin University School of Medicine, Yokohoma, Japan, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 6Immunology, Janssen Research & Development, LLC, Titusville, NJ, 7Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, 8McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, 9The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 10Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
  • Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium

    An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients

    Sarah Campbell1, Rosemary Peterson2, Sarah Barrientos3, Elinore Benett3 and Cori Christenholz3, 1University of Texas at Austin Dell Medical School, Austin, TX, 2Dell Medical School at UT Austin, Austin, TX, 3Dell Children's Medical Center Department of Rheumatology, Austin, TX

    Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…
  • Abstract Number: 0699 • ACR Convergence 2022

    Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Alexis Ogdie1, Jacqueline O'Brien2, Wendi Malley2, Elizabeth Kohl2, Kate Orroth3, Yuri Klyachkin4, Myriam Cordey5 and Philip J Mease6, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3Amgen, Manhattan Beach, CA, 4Amgen, Lexington, KY, 5Amgen, Inc., Thousand Oaks, CA, 6Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
  • Abstract Number: 0891 • ACR Convergence 2022

    Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity

    Sultana Abdulaziz1, Suzan Attar2, Renad Ahmed2, Hamza Fida2, Omar Bokhary2, Anas Alyazidi2 and Abdulelah Abumohssin2, 1King Fahad Hospital, Jeddah, Saudi Arabia, 2King Abdulaziz University, Jeddah, Saudi Arabia

    Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology